Skip to Main Content

In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug after the manufacturer of a rival medicine claimed that Health Canada had originally issued an “incorrect and unreasonable” endorsement.

In a 63-page ruling, Justice Martine St-Louis set aside the approval issued by the regulator last year. As a result, the government will now have to review the marketing file submitted by Jacobus Pharmaceuticals, a small, family-run company that sells a drug to treat people with a rare neuromuscular disorder called Lambert-Eaton myasthenic syndrome, or LEMS. A competitor, Catalyst Pharmaceuticals (CPRX), is seeking to push back the approval until 2028. We asked Jacobus and Health Canada for comment and will update you accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!